



## ***Corporate Governance prize awarded by AGEFI: Onxeo receives “Silver Governance”***

**Paris (France), Copenhagen (Denmark), September 25, 2014** – Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, was awarded the Silver Governance in the Corporate Governance Prize (for midcap companies) category at the Eleventh Annual Awards, held by the French economic and financial magazine AGEFI on September 24, 2014.

Corporate Governance Prizes reward listed companies with the best corporate governance practices - in particular as regards to the composition of the companies' board of directors, transparency of communication, functioning of corporate bodies, social responsibility, and risk management. The awards are based on the results of a survey of finance industry professionals. The methodology is validated by a steering committee which identifies the companies' good practices based on data provided in the annual report and reference document.

For several years now, Onxeo has optimized its governance practices: the company refers to the corporate governance code established by MiddleNext\*. Its Board of Directors is mostly composed of independent members, who are very committed alongside the Management, and is governed by internal regulation; a code of conduct has been implemented. The Company strives to communicate regularly and precisely on its programs, achievements and accounts.

These elements, rewarded by the financial community through this “Silver Governance” and decisive in strengthening confidence from shareholders and share markets, come in addition to high-standard quality applied to all company's activities, in particular in R&D.

*“We are very proud and happy to be awarded with this prize which confirms the excellence of our governance, with efficient committees, processes, and regulations, all key components to carry out our mission and achieve our goals to create value. This prize, which places Onxeo alongside world-class companies such as Boiron and Guerbet, reflects our ambition in the area of orphan oncology drugs”,* comments Patrick Langlois, Chairman of the Board of Directors of Onxeo.

\*MiddleNext is an independent French association representing listed SMEs and midcaps

### **About Onxeo**

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives.

### **Key products at advanced development stage are:**

Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma  
Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis

Beleodaq® (belinostat): Registered and available in the USA for peripheral T-cell lymphoma  
For more information, visit the website [www.onxeo.com](http://www.onxeo.com)

**Disclaimer**

*This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference Document filed with the AMF on April 7, 2014, which is available on the AMF website (<http://www.amf-france.org>) or on the company's website ([www.onxeo.com](http://www.onxeo.com)).*

**Contacts :**

Judith Greciet, CEO  
[j.greciet@onxeo.com](mailto:j.greciet@onxeo.com)  
+33 1 45 58 76 00

Nicolas Fellmann, CFO  
[n.fellmann@onxeo.com](mailto:n.fellmann@onxeo.com)  
+33 1 45 58 76 00

Caroline Carmagnol / Sophie Colin – Alize RP  
[caroline@alizerp.com](mailto:caroline@alizerp.com) / [scolin@alizerp.com](mailto:scolin@alizerp.com)  
+33 6 64 18 99 59 / +33 6 31 13 76 20